$2.37 1.7%
EDIT Stock Price vs. AI Score
Data gathered: November 22

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Editas Medicine (EDIT)

Analysis generated November 10, 2024. Powered by Chat GPT.

Editas Medicine is a leading gene editing company focused on developing transformative genome editing treatments aimed at enabling precise genetic modifications. The company leverages its proprietary CRISPR technology to address various genetic disorders. Editas Medicine is positioned at the forefront of biotechnology, aiming to develop therapies that can potentially cure a range of severe ailments including ocular, blood, and neurological diseases.

Read full AI stock Analysis

Stock Alerts - Editas Medicine (EDIT)

company logo Editas Medicine | November 20
Price is down by -5% in the last 24h.
company logo Editas Medicine | November 18
Price is down by -5.3% in the last 24h.
company logo Editas Medicine | November 15
Price is down by -5.8% in the last 24h.
company logo Editas Medicine | November 14
Price is down by -5.4% in the last 24h.

About Editas Medicine

Editas Medicine is a clinical-stage biotechnology company which is developing therapies based on CRISPR–Cas9 gene editing technology. Editas is based in Cambridge, Massachusetts and has facilities in Boulder, Colorado.


Editas Medicine
Price $2.37
Target Price Sign up
Volume 2,890,000
Market Cap $199M
Year Range $2.37 - $8.13
Dividend Yield 0%
Analyst Rating 60% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '2461,00018M-18M-62M0-0.750
Q2 '24510,00018M-18M-68M-70M-0.820
Q1 '241.1M19M-18M-62M-66M-0.760
Q4 '2362M14M47M-19M-22M-0.230
Q3 '235.3M15M-9.7M-45M-45M-0.550

Insider Transactions View All

Mei Baisong filed to sell 133,895 shares at $3.4.
September 6 '24
O'Neill Gilmore Neil filed to sell 313,724 shares at $3.4.
September 6 '24
Burkly Linda filed to sell 73,136 shares at $5.4.
July 26 '24
Mei Baisong filed to sell 134,413 shares at $5.2.
July 22 '24
Mei Baisong filed to sell 141,032 shares at $5.5.
June 6 '24

What is the Market Cap of Editas Medicine?

The Market Cap of Editas Medicine is $199M.

What is the current stock price of Editas Medicine?

Currently, the price of one share of Editas Medicine stock is $2.37.

How can I analyze the EDIT stock price chart for investment decisions?

The EDIT stock price chart above provides a comprehensive visual representation of Editas Medicine's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Editas Medicine shares. Our platform offers an up-to-date EDIT stock price chart, along with technical data analysis and alternative data insights.

Does EDIT offer dividends to its shareholders?

As of our latest update, Editas Medicine (EDIT) does not offer dividends to its shareholders. Investors interested in Editas Medicine should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Editas Medicine?

Some of the similar stocks of Editas Medicine are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.